A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder

Journal of the American Academy of Child and Adolescent Psychiatry
Jeffrey R StrawnRobert L Findling

Abstract

To evaluate the efficacy, safety, and tolerability of the selective serotonin norepinephrine inhibitor duloxetine in children and adolescents with generalized anxiety disorder (GAD). Youth aged 7 through 17 years with a primary diagnosis of GAD were treated with flexibly dosed duloxetine (30-120 mg daily, n = 135) or placebo (n = 137) for 10 weeks, followed by open-label duloxetine (30-120mg daily) for 18 weeks. Efficacy measures included the Pediatric Anxiety Rating Scale (PARS), Clinical Global Impression-Severity (CGI-Severity) scale, and Children's Global Assessment Scale (CGAS). Safety measures included the Columbia-Suicide Severity Rating Scale (C-SSRS) as well as vital signs and electrocardiographic and laboratory monitoring. On the primary efficacy measure (PARS severity for GAD), mean improvement from baseline to 10 weeks was statistically significantly greater for duloxetine (-9.7) compared with placebo (-7.1, p ≤ .001, Cohen's d: 0.5). Symptomatic response (50% improvement on the PARS severity for GAD), remission (PARS severity for GAD ≤8), and functional remission (CGAS >70) rates for the duloxetine group (59%, 50%, 37%, respectively) were statistically significantly greater than for the placebo group (42%, 34%, 24%...Continue Reading

References

Nov 1, 1983·Archives of General Psychiatry·D ShafferS Aluwahlia
Feb 27, 1981·Science·C R LakeF C Bartter
Sep 15, 2001·Journal of the American Academy of Child and Adolescent Psychiatry·L J Woodward, D M Fergusson
Sep 10, 2002·Journal of the American Academy of Child and Adolescent Psychiatry
Nov 13, 2002·Journal of Child and Adolescent Psychopharmacology·John WalkupUNKNOWN Research Units on Pediatric Psychopharmacology Anxiety Study Group
Sep 24, 2004·Psychosomatic Medicine·Jeffrey R StrawnThomas D Geracioti
Jan 12, 2005·Depression and Anxiety·Denise A ChaviraMartin T Stein
Sep 6, 2006·Archives of General Psychiatry·Debra L FoleyAdrian Angold
Nov 1, 2008·The New England Journal of Medicine·John T WalkupPhilip C Kendall
Dec 3, 2008·The American Journal of Psychiatry·Jeffrey A BridgeDavid A Brent
Sep 1, 2009·The Psychiatric Clinics of North America·Katja BeesdoDaniel S Pine
Jan 6, 2010·Archives of General Psychiatry·Katja BeesdoHans-Ulrich Wittchen
Mar 25, 2010·The Journal of Clinical Psychiatry·David V SheehanBerney Wilkinson
Jan 1, 2009·International Journal of General Medicine·Alan Wright, Chad Vandenberg
Sep 22, 2010·Journal of the American Academy of Child and Adolescent Psychiatry·Kathleen Ries MerikangasJoel Swendsen
Jan 14, 2011·Journal of Psychiatric Research·Katja Beesdo-BaumHans-Ulrich Wittchen
Nov 30, 2011·Journal of Consulting and Clinical Psychology·Golda S GinsburgJohn March
Jan 19, 2012·Journal of Child and Adolescent Psychopharmacology·Apurva PrakashJohn S March
Jul 18, 2012·Child and Adolescent Psychiatric Clinics of North America·Jeffrey R StrawnMoira A Rynn
Aug 23, 2012·Psychiatric Services : a Journal of the American Psychiatric Association·Mathilde M HuskyKathleen Ries Merikangas
Dec 26, 2012·Journal of the American Academy of Child and Adolescent Psychiatry·Nicole E CaporinoJohn T Walkup
Jan 16, 2013·The American Journal of Psychiatry·Bret R Rutherford, Steven P Roose
May 13, 2014·Journal of Child and Adolescent Psychopharmacology·Sarah D AtkinsonJohn S March
May 13, 2014·Journal of Child and Adolescent Psychopharmacology·Graham J EmslieJohn S March

❮ Previous
Next ❯

Citations

Jan 12, 2016·International Journal of Psychiatry in Clinical Practice·Marco PozziMaria Nobile
Mar 31, 2016·Journal of Child and Adolescent Psychopharmacology·Eric T Dobson, Jeffrey R Strawn
Apr 12, 2016·Academic Pediatrics·Lisa L Giles, D Richard Martini
Feb 7, 2017·Journal of Child and Adolescent Psychopharmacology·Jeffrey R StrawnMoira A Rynn
Apr 7, 2017·Journal of Child and Adolescent Psychopharmacology·Jeffrey R StrawnMoira A Rynn
Aug 29, 2017·Journal of Child and Adolescent Psychopharmacology·Jeffrey R StrawnPaul E Croarkin
May 4, 2016·Journal of Psychiatric Practice·Tabatha H MeltonShawn M McClintock
May 20, 2015·Current Psychiatry Reports·Anna M WehryJeffrey R Strawn
Jun 6, 2020·Journal of Child Psychology and Psychiatry, and Allied Disciplines·Jeffrey R StrawnJohn T Walkup
Sep 21, 2016·Current Treatment Options in Psychiatry·Farah S HussainJeffrey R Strawn
Nov 5, 2019·Journal of the American Academy of Child and Adolescent Psychiatry·Jeffrey A Mills, Jeffrey R Strawn
Nov 14, 2020·Journal of Child and Adolescent Psychopharmacology·Brittany McCoyBarbara J Coffey
Jan 13, 2018·Current Problems in Pediatric and Adolescent Health Care·Anna M WehryJeffrey R Strawn
Jan 24, 2018·Current Problems in Pediatric and Adolescent Health Care·Marissa J LuftJeffrey R Strawn
Sep 25, 2021·Journal of Child and Adolescent Psychopharmacology·Madeeha NasirMichael H Bloch

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.